EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Cooper McDonald on September 01, 2009.

IN THE CLAIMS –

Please **replace** claims dated on 06/11/2009 to the following claims:

"1-71. (Canceled).

72. (Previously presented) A compound having the structural formula (A),



(A)

wherein:

- the dotted lines represent an optional double bond, provided that no two double bonds are adjacent to one another, and that the dotted lines represent at least 3 double bonds;

- R^1 is selected from the group consisting of aryl, heterocycle, C_1-C_{10} alkoxy, C_1-C_{10} thioalkyl, C_1-C_{10} alkyl-amino, C_1-C_{10} dialkylamino, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, and C_{4-10} cycloalkynyl, wherein each is optionally substituted with one or more R^6;
- Y is selected from a single bond, O, $S(O)_m$, NR^{11}, C_{1-10} alkylene, C_{2-10} alkenylene, or C_{2-10} alkynylene, wherein each alkylene, alkenylene or alkynylene optionally includes 1 to 3 heteroatoms selected from O, S or N;
- R^2 and R^4 are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, halogen, -OH, -CN, $-NO_2$, $-NR^7R^8$, haloalkyloxy, haloalkyl, $-C(=O)R^9$, $-C(=S)R^9$, -SH, aryl, aryloxy, arylthio, arylalkyl, C_{1-18} hydroxyalkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyloxy, C_{3-10} cycloalkylthio, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, and heterocycle, or when one of R^{25} or R^{26} is present, R^2 or R^4 is selected from the group consisting of (=O), (=S), and $=NR^{27}$;
- X is selected from the group consisting of C_1-C_{10} alkylene, C_{2-10} alkenylene and C_{2-10} alkynylene, where each optionally includes one or more heteroatoms selected from the group consisting of O, S, or N, provided any such heteroatom is not adjacent to the N in the imidazopyridyl ring;
- m is any integer from 0 to 2;
- R^3 is a heterocycle substituted with one or more R^{17}, provided that R^3 optionally substituted with at least one R^{17} is not pyridinyl or 5-chlorothienyl;
- R^5 is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, halogen, -OH, -CN, $-NO_2$, $-NR^7R^8$, haloalkyloxy, haloalkyl, $-C(=O)R^9$, $-C(=O)OR^9$, $-C(=S)R^9$, SH, aryl, aryloxy, arylthio, arylalkyl, C_{1-18} hydroxyalkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyloxy, C_{3-10} cycloalkylthio, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, and heterocycle;

- each R^6 is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, C_{1-18} alkylsulfoxide, C_{1-18} alkylsulfone, C_{1-18} halo-alkyl, C_{2-18} halo-alkenyl, C_{2-18} halo-alkynyl, C_{1-18} halo-alkoxy, C_{1-18} halo-alkylthio, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, $-CO_2R^{18}$, $-NO_2$, $-NR^7R^8$, C_{1-18} haloalkyl, $-C(=O)R^{18}$, $-C(=S)R^{18}$, -SH, aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, aryl(C_{1-18})alkyl, aryl(C_{1-18})alkyloxy, aryl(C_{1-18})alkylthio, heterocycle and C_{1-18} hydroxyalkyl, where each is optionally substituted with one or more R^{19};
- R^7 and R^8 are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{1-18} alkenyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, heterocycle, $-C(=O)R^{12}$; $-C(=S)R^{12}$, and an amino acid residue linked through a carboxyl group thereof, or R^7 and R^8 are taken together with the nitrogen to form a heterocycle;
- R^9 and R^{18} are independently selected from the group consisting of hydrogen, -OH, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{1-18} alkoxy, $-NR^{15}R^{16}$, aryl, an amino acid residue linked through an amino group of the amino acid, $-CH_2OCH(=O)R^{9a}$, and $-CH_2OC(=O)OR^{9a}$ where R^{9a} is C_1-C_{12} alkyl, C_6-C_{20} aryl, C_6-C_{20} alkylaryl or C_6-C_{20} aralkyl;
- R^{11} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, aryl, $-C(=O)R^{12}$, heterocycle, and an amino acid residue;
- R^{12} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, and an amino acid residue;
- R^{15} and R^{16} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, and an amino acid residue;

- each R^{17} is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, C_{1-18} alkylsulfoxide, C_{1-18} alkylsulfone, C_{2-18} halogenated alkenyl, C_{2-18} halogenated alkynyl, C_{2-18} halogenated alkoxy, C_{1-18} halogenated alkylthio, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, halogen, OH, CN, NO_2, NR^7R^8, haloalkyl, $C(=O)R^{18}$, $C(=S)R^{18}$, SH, aryl, aryloxy, arylthio, CO_2H, CO_2R^{18}, arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl, arylalkyloxy, arylalkylthio, heterocyclic, and C_{1-18} hydroxyalkyl, where each of said aryl, aryloxy, arylthio, arylalkyl, arylalkyloxy, arylalkylthio, heterocycle, C_{1-18} hydroxyalkyl, arylsulfoxide, arylsulfone, or arylsulfonamide is optionally substituted with one or more R^{19};
- each R^{19} is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{2-18} alkenyloxy, C_{2-18} alkynyloxy, C_{1-18} alkylthio, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{4-10} cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, $-NO_2$, $-NR^{20}R^{21}$, C_{1-18} haloalkyl, C_{1-18} haloalkyloxy, $-C(=O)R^{18}$, $-C(=O)OR^{18}$, $-OalkenylC(=O)OR^{18}$, $-OalkylC(=O)NR^{20}R^{21}$, $-OalkylOC(=O)R^{18}$, $-C(=S)R^{18}$, SH, $-C(=O)N(C_{1-6}$ alkyl), $-N(H)S(O)(O)(C_{1-6}$ alkyl), aryl, heterocycle, C_{1-18} alkylsulfone, arylsulfoxide, arylsulfonamide, aryl(C_{1-18})alkyloxy, aryloxy, aryl(C_{1-18} alkyl)oxy, arylthio, aryl(C_{1-18})alkylthio and aryl(C_{1-18})alkyl, where each is optionally substituted with 1 or more =O, $-NR^{20}R^{21}$, -CN, C_{1-18} alkoxy, heterocycle, C_{1-18} haloalkyl, heterocycle alkyl, heterocycle connected to R^{17} by alkyl, alkoxyalkoxy or halogen;
- R^{20} and R^{21} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, $-C(=O)R^{12}$, carboxylester-substituted heterocycle, and $-C(=S)R^{12}$;

- R^{25} and R^{26} are not present, or are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{3-10} cycloalkyl, aryl and heterocycle, where each is optionally independently substituted with 1 to 4 of C_{1-6} alkyl, C_{1-6} alkoxy, halo, $-CH_2OH$, benzyloxy, and -OH; and
- R^{27} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{3-10} cycloalkyl, (C_{3-10} cycloalkyl)-C_{1-6} alkyl, aryl, and aryl(C_{1-18})alkyl; and salts, tautomers, and stereoisomers thereof.

73. – 78. (Cancelled)

79. (Currently amended) A compound having the structural formula (C)



(C)

wherein:

- R^1 is selected from the group consisting of aryl, heterocycle, C_1-C_{10} alkoxy, C_1-C_{10} thioalkyl, C_1-C_{10} alkyl-amino, C_1-C_{10} dialkylamino, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, and C_{4-10} cycloalkynyl, wherein each is optionally substituted with one or more R^6;
- Y is selected from a single bond, O, $S(O)_m$, NR^{11}, C_{1-10} alkylene, C_{2-10} alkenylene, or C_{2-10} alkynylene, wherein each alkylene, alkenylene or alkynylene optionally includes 1 to 3 heteroatoms selected from O, S or N;

- R^2 and R^4 are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, halogen, -OH, -CN, -NO_2, -NR^7R^8, haloalkyloxy, haloalkyl, -C(=O)R^9, -C(=S)R^9, -SH, aryl, aryloxy, arylthio, arylalkyl, C_{1-18} hydroxyalkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyloxy, C_{3-10} cycloalkylthio, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, and heterocycle;
- X is selected from the group consisting of C_1-C_{10} alkylene, C_{2-10} alkenylene and C_{2-10} alkynylene, where each optionally includes one or more heteroatoms selected from the group consisting of O, S, or N, provided any such heteroatom is not adjacent to the N in the imidazopyridyl ring;
- m is any integer from 0 to 2;
- R^3 is aryl, aryloxy, arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl-N(R^{10})-, or heterocycle, each of which is optionally substituted with one or more R^{17}, provided that for cycloalkenyl the double bond is not adjacent to a nitrogen, provided M-Q-R^3 is not biphenyl, and provided that R^3 substituted with at least one R^{17} is not pyridinyl or 5-chlorothienyl;
- R^5 is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, halogen, -OH, -CN, -NO_2, -NR^7R^8, haloalkyloxy, haloalkyl, -C(=O)R^9, -C(=O)OR^9, -C(=S)R^9, -SH, aryl, aryloxy, arylthio, arylalkyl, C_{1-18} hydroxyalkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyloxy, C_{3-10} cycloalkylthio, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, and heterocycle;
- each R^6 is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, C_{1-18} alkylsulfoxide, C_{1-18} alkylsulfone, C_{1-18} halo-alkyl, C_{2-18} halo-alkenyl, C_{2-18} halo-alkynyl, C_{1-18} halo-alkoxy, C_{1-18} halo-alkylthio, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, -CO_2R^{18}, -NO_2, -NR^7R^8, C_{1-18} haloalkyl, -C(=O)R^{18}, -C(=S)R^{18}, -SH, aryl, aryloxy,

arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, aryl(C_{1-18})alkyl, aryl(C_{1-18})alkyloxy, aryl(C_{1-18})alkylthio, heterocycle and C_{1-18} hydroxyalkyl, where each is optionally substituted with one or more R^{19};

- R^7 and R^8 are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{1-18} alkenyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, heterocycle, -C(=O)R^{12}; -C(=S) R^{12}, and an amino acid residue linked through a carboxyl group thereof, or R^7 and R^8 are taken together with the nitrogen to form a heterocycle;
- R^9 and R^{18} are independently selected from the group consisting of hydrogen, -OH, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{1-18} alkoxy, -$NR^{15}R^{16}$, aryl, an amino acid residue linked through an amino group of the amino acid, -$CH_2OCH(=O)R^{9a}$, and -$CH_2OC(=O)OR^{9a}$ where R^{9a} is C_1-C_{12} alkyl, C_6-C_{20} aryl, C_6-C_{20} alkylaryl or C_6-C_{20} aralkyl;
- R^{10} and R^{11} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, aryl, -C(=O)R^{12}, heterocycle, and an amino acid residue;
- R^{12} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, and an amino acid residue;
- R^{15} and R^{16} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, and an amino acid residue;
- each R^{17} is independently MQ- wherein M is a ring optionally substituted with one or more R^{19}, and Q is a bond or a linking group connecting M to R^3 that has 1 to 10 atoms and is optionally substituted with one or more R^{19}, <u>wherein the linking group is alkylene optionally substituted with oxy or thioester</u>;
- each R^{19} is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{2-18} alkenyloxy, C_{2-18}

alkynyloxy, C_{1-18} alkylthio, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{4-10} cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, $-NO_2$, $-NR^{20}R^{21}$, C_{1-18} haloalkyl, C_{1-18} haloalkyloxy, $-C(=O)R^{18}$, $-C(=O)OR^{18}$, $-OalkenylC(=O)OR^{18}$, $-OalkylC(=O)NR^{20}R^{21}$, $-OalkylOC(=O)R^{18}$, $-C(=S)R^{18}$, -SH, $-C(=O)N(C_{1-6}$ alkyl), $-N(H)S(O)(O)(C_{1-6}$ alkyl), aryl, heterocycle, C_{1-18} alkylsulfone, arylsulfoxide, arylsulfonamide, aryl(C_{1-18})alkyloxy, aryloxy, aryl(C_{1-18} alkyl)oxy, arylthio, aryl(C_{1-18})alkylthio or aryl(C_{1-18})alkyl, where each is optionally substituted with 1 or more =O, $-NR^{20}R^{21}$, -CN, C_{1-18} alkoxy, heterocycle, C_{1-18} haloalkyl, heterocycle alkyl, heterocycle connected to R^{17} by alkyl, alkoxyalkoxy and halogen;

- R^{20} and R^{21} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, $-C(=O)R^{12}$, and ~~or~~ $-C(=S)R^{12}$;
- ~~and~~

and salts, tautomers, and stereoisomers thereof.

80. (Cancelled)

81. (Previously presented) A compound according to claim 72, wherein R^3 is isoxazolyl substituted with one to three R^{17}.

82.-85. (Cancelled)

86. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to claim 72.

87. -89. (Cancelled)

90. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to claim 79.

91. (Previously presented) The compound of claim 72, wherein YR^1 is halophenyl or halomethyl-substituted phenyl.

92. (Previously presented) The compound of claim 91, wherein halophenyl is ortho-fluorophenyl.

93. (Previously presented) The compound of claim 72, wherein R^{17} is aryl or a heterocycle further substituted with 1, 2 or 3 R^{19}.

94. (Previously presented) The compound of claim 72, wherein YR^1 is not an unsubstituted C_{3-10} cycloalkyl.

95. (Previously presented) The compound of claim 72 wherein R^{19} is trihalomethyl, trihalomethoxy, alkoxy or halogen.

96. (Previously presented) The compound of claim 72, wherein R^1 is aryl or aromatic heterocyle substituted with 1, 2 or 3 R^6 and wherein R^6 is halogen, C_{1-18} alkoxy or C_{1-18} haloalkyl.

97. (Previously presented) The compound of claim 72, wherein Y is a bond.

98. (Previously presented) The compound of claim 72, wherein X is selected from the group consisting of $-CH_2-$, $-CH(CH_3)-$, $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH_2-$

CH_2-CH_2-CH_2, -$(CH_2)_{2-4}$-O-$(CH_2)_{2-4}$-, -$(CH_2)_{2-4}$-S-$(CH_2)_{2-4}$-, -$(CH_2)_{2-4}$-NR^{10}-$(CH_2)_{2-4}$-, C_{3-10} cycloalkylidene, C_{2-6} alkenylene and C_{2-6} alkynylene, wherein R^{10} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, aryl, -C(=O)R^{12}, heterocyclic, and an amino acid residue.

99. (Previously presented) The compound of claim 72, wherein X is methylene.

100. (Previously presented) The compound of claim 72, wherein R^3 is a heterocycle substituted with 0 to 3 R^{17}.

101. (Previously presented) The compound of claim 100, wherein the R^3 is an aromatic heterocycle.

102. (Previously presented) The compound of claim 101, wherein the heterocycle contains 1, 2 or 3 N, S or O atoms in the ring, is linked to X through a ring carbon atom and contains 4 to 6 total ring atoms.

103. (Previously presented) The compound of claim 72, wherein R^{17} is selected from the group consisting of C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl; arylalkyloxy; arylalkylthio and heterocycle, each being unsubstituted or substituted with 1 or more $R^{19.}$

104. (Previously presented) The compound of claim 72, wherein R^9 and R^{18} are H, OH or alkyl.

105. (Previously presented) The compound of claim 72, wherein R^5 is H.

106. (Previously presented) The compound of claim 72, wherein R^6 is halogen.

107. (Previously presented) The compound of claim 72, wherein R^7, R^8, R^{11}, R^{15}, R^{16}, R^{20}, and R^{21} are independently H or C_{1-18} alkyl.

108. (Previously presented) The compound of claim 72, wherein R^{12} is OH or alkyl.

109. (Previously presented) The compound of claim 72, wherein R^{19} is selected from the group consisting of H; C_{1-18} alkyl; C_{2-18} alkenyl; C_{2-18} alkynyl; C_{1-18} alkoxy; alkenyloxy; alkynyloxy; C_{1-18} alkylthio; C_{3-10} cycloalkyl; C_{4-10} cycloalkenyl; C_{4-10} cycloalkynyl; halogen; OH; CN; cyanoalkyl; NO_2; $NR^{20}R^{21}$; haloalkyl; haloalkyloxy; $C(=O)R^{18}$; $C(=O)OR^{18}$; $OalkenylC(=O)OR^{18}$; -$OalkylC(=O)NR^{20}R^{21}$; aryl; heterocycle; -$OalkylOC(=O)R^{18;}$ $C(=O)N(C_{1-6}$ alkyl), $N(H)S(O)(O)(C_{1-6}$ alkyl); arylalkyloxy; aryloxy; arylalkyloxy; and arylalkyl; each of which is unsubstituted or substituted with 1 or more =O; $NR^{20}R^{21}$; CN; alkoxy; heterocycle; haloalkyl- or alkyl-substituted heterocycle; and heterocycle linked to R^{17} by alkyl; alkoxyalkoxy and halogen.

110. (Previously presented) The compound of claim 109, wherein R^{19} is independently selected from the group consisting of halogen, $NR^{20}R^{21}$, alkoxy, halo-substituted alkyl and halo-substituted alkoxy.

111. (Previously presented) The compound of claim 72, wherein R^{25} and R^{26} are not present.

112. (Previously presented) The compound of claim 72, wherein haloalkyl or haloalkyloxy is $–CF_3$ or $-OCF_3$.

113. (Previously presented) The compound of claim 72, wherein Y is a single bond, and R^1 is phenyl.

114. (Previously presented) The compound of claim 79, wherein Y is a single bond, and R^1 is aryl.

115. (Previously presented) The compound of claim 79, wherein X is C_1-C_{10} alkylene, C_{2-10} alkenylene or C_{2-10} alkynylene.

116. (Previously presented) The compound of claim 79, wherein R^3 is a heterocyle.

117. (Previously presented) The compound of claim 79, wherein R^3 is a heterocycle substituted with R^{17} where Q is a bond and M is aryl.

118. (Previously presented) The compound of claim 79, wherein R^3 is isoxazole substituted with R^{17} where Q is a bond and M is aryl.

119. – 125. (Cancelled) “

Allowable Subject Matter

Claims 72, 79, 81, 86, 90-118 are allowed.

The following is an examiner's statement of reasons for allowance:

Claim 79 were rejected under 1039a) over Cardozo et al., WO 2004067516 in the previous office action and the rejection is withdrawn in light of applicant's amendment argument in the paper dated on 02/11/2009.

Any comments considered necessary by applicant must be submitted no late than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/NILOOFAR RAHMANI/

09/03/2009

/D. Margaret Seaman/
Primary Examiner, Art Unit 1625